Results - Announcements
Marksans Pharma Ltd share price inched up 0.86% to Rs 315.1 after the company's net profit eased 9.96% to Rs 143.53 crore, while revenue from operations increased 11.82% to Rs 940.17 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, gaining 4.49%. It has marginally improved by 1.84% over last one week and crept higher by 1.37% in last one month while the market capitalization of Marksans Pharma Ltd has improved by 3.24% and 17.12% in the same period respectively.
Profit before tax (PBT) of Marksans Pharma Ltd stood at Rs 193.5 crore in Q3 FY26, expanding by 45.13% year-on-year, and slipping 6.33% quarter-on-quarter. EBITDA came in at Rs 196 crore, rallying 59.55% YoY and easing 4.54% sequentially.
Total expenses rose by 16.14% to Rs 757.99 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 231.49 crore, posting a minor increase of 4.90% YoY, while employee benefits expense was at Rs 122.32 crore, registering a growth of 7.03% YoY.
For the TTM ended FY26, revenue from operations grew 12.51% to Rs 2950.94 crore, while net profit saw a marginal increase of 9.79% to Rs 420.06 crore, compared to previous TTM. EBITDA jumped by 48060% to Rs 518.25 crore, and PBT improved 11.23% to Rs 560.56 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 458.13 crore in FY26, as against Rs 206.66 crore in FY25.
Marksans Pharma Ltd soared by 65.45% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 8.41% during the same period.